Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 627 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alcoholic Liver Disease Clear all
Completed Phase 2 Interventional Results available

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NCT05415722
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-501, TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
35
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 10, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

NCT03294941
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HepQuant SHUNT Liver Diagnostic Kit
Combination Product
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Dallas, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

NCT02854631
View directory record Official record
Conditions
Alcoholic Hepatitis (AH)
Interventions
Selonsertib, Prednisolone, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
11
States / cities
Little Rock, Arkansas • Coronado, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 10, 2026, 10:13 AM EDT
Not listed Phase 1 Interventional

Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study

NCT02469272
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Fecal Microbiota Transplantation
Drug
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 10, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
141
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT02912260
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
MGL-3196, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 10, 2026, 10:13 AM EDT
Not listed Not applicable Interventional

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

NCT03388320
View directory record Official record
Conditions
Liver Diseases, Alcoholic
Interventions
A-CHESS
Device
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease

NCT01327443
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

NCT01792115
View directory record Official record
Conditions
Fatty Liver
Interventions
Vitamin E 200 IU/d, Vitamin E 400 IU/d, Vitamin E 800 IU/d, Diet and Exercise
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Interventions
Nitazoxanide 500mg BID
Drug
Lead sponsor
Pinnacle Clinical Research, PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 10, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

NCT00536250
View directory record Official record
Conditions
Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
8 Years to 22 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Gemcabene in Adults With FPLD

NCT03508687
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
300mg Gemcabene, 600mg Gemcabene
Drug
Lead sponsor
Elif Oral
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 10, 2026, 10:13 AM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

NCT03696797
View directory record Official record
Conditions
Iron, Diabetes, Nonalcoholic Fatty Liver
Interventions
Blood Donation, Sham Blood Donation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150
View directory record Official record
Conditions
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Tocotrienol Against the Progression of End Stage Liver Disease

NCT02581085
View directory record Official record
Conditions
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Tocotrienol (TCT), Placebo
Drug · Other
Lead sponsor
Chandan Sen
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Completed No phase listed Observational

Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis

NCT02075918
View directory record Official record
Conditions
Alcoholic Hepatitis, Control Patients
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 10, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

NCT02116192
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
11 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 10, 2026, 10:13 AM EDT
Recruiting Phase 3 Interventional

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
126
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

NCT06335771
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Interventions
Dietary consultation weight loss intervention
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 10, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity

NCT00878592
View directory record Official record
Conditions
Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity, Nonalcoholic Steatohepatitis
Interventions
Dietary and life style modification
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 10, 2026, 10:13 AM EDT